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Having spent most of my career studying viral infections
and their clinical manifestations, in particular AIDS, I have
developed a keen interest in the incubation of diseases. In
recent years I have focused my attention on Alzheimer’s
disease (AD), so for me the key question concerning this
illness is: when does AD start to develop? AD is tentatively
diagnosed on the basis of a set of clinical symptoms
(progressive irreversible decline in memory and other
cognitive functions) and confirmed by neuropathology
(brain atrophy accompanied by the accumulation of abun-
dant extracellular amyloid b plaques and intraneuronal
neurofibrillary tau lesions) [1] (Fig. 1a).
The comparison of AD with AIDS is informative in many
ways, even though I do not think that AD is a transmissible or
infectious disease [2]. The human retrovirus HIV is both
necessary and sufficient to cause AIDS. Following an HIV
infection, clinical symptoms defining AIDS can develop
within months after infection, but it can also take a decade for
AIDS symptoms to appear, depending on the amount of virus
continuously produced by CD4? T cells. The number of
CD4? T cells decreases due to the HIV infection, and this
decrease—to far below the normal physiological threshold—
is a hallmark of ongoing HIV infection and continuous
production of virus by CD4? T cells. Therefore, the risk of
developing AIDS is defined by acquiring the virus in an all-
or-nothing manner and the time to disease is defined by the
virus load, which may vary from the beginning of infection.
Consequently, the level of risk to get AIDS can be measured
by a qualitative serum biomarker seroconversion (from
antibody negative to positive) and a quantitative serum bio-
marker increase (from low to high antigen level) [3–11]
(Fig. 1b).
Avoiding the (age-independent) risk to acquire HIV
prevents AIDS altogether; after the virus has been acquired,
combination therapy with antiretroviral drugs reduces the
virus load and as a consequence AIDS manifestations are
postponed as long as no viral resistance occurs (Fig. 1c).
This provides the final proof that HIV causes AIDS.
If we extrapolate these findings to AD, we can ask: will we
all get AD if we live long enough? In other words, are we all
incubating AD, but are some individuals closer to manifest
the disease than others? Or is the risk to develop AD not
evenly distributed? Let’s do a thought experiment to examine
these questions. Let us start with the idea that AD is a
manifestation of biological aging, and that some people may
age faster and others slower than the year-by-year progres-
sion of calendar age. This can be considered the cause of AD
(necessary and sufficient), a significant contributor to the
disease (necessary but not sufficient) or a confounder in the
classical sense (Fig. 2a). An elegant study by Belsky et al.
[12] recently showed that biological age is normally dis-
tributed in a cohort of 38-year-olds. While this study inclu-
ded only individuals aged 38 years from the Dunedin Study
birth cohort, the biological age of these individuals ranged
from 28 to 61 years of age [12]. Biological age was calcu-
lated using the Klemera–Doubal algorithm [13] that was
validated in the US National Health and Nutrition Survey
(NHANES) III dataset [14]. Individuals with an accelerated
pace of aging had poorer cognitive function and this differ-
ence in cognitive function reflected measurable cognitive
decline over the years. Whether this aging effect predicts the
eventual development of clinically manifest AD decades
later, remains to be established in longitudinal cohort studies
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(Fig. 2b). If so, do the individuals who age slower or at an
average pace in midlife die of old age without AD?
Morgan Levine et al. from the University of California,
Los Angeles (UCLA) recently conducted another study of
biological brain age, determined not by the Klemera–Doubal
algorithm based on simple blood chemistry, viral antibody in
serum or plasma and a few clinical tests, but using the so-
called ‘epigenetic clock’ designed and built by Steve Hor-
vath of UCLA [15]. The Levine study examined 700 pre-
frontal cortex samples from Caucasian participants in the
Religious Order Study and the Rush Memory and Aging
Project, gathering data that suggest that acceleration of
biological brain age may be associated with amyloid plaque
formation, global cognitive functioning, and episodic
memory decline [16]. Levine et al. postulate that aging of
the brain may contribute to or even cause the misfolding,
aggregation and spreading of both pathological tau (p-tau)
and amyloid coinciding with memory loss. Previously,
Horvath et al. have shown that blood may be a promising
surrogate for brain tissue to determine overall brain age, as
the Belsky study independently suggests [12, 17].
It would be extremely helpful if sensitive and specific
serum or plasma biomarkers with adequate negative and
positive predictive value were available to help establish
the risk for AD during the asymptomatic incubation period.
This is currently not the case. Although cerebrospinal fluid
(CSF) antigen tests for amyloid and tau have been devel-
oped (by Innogenetics, Ghent, Belgium; and Thermo Fisher
Scientific, Waltham, MA, USA), these tests are impractical
for population screening and blood markers are not yet well
established [18–21]. The diagnosis of AD can currently be
confirmed post-mortem by immunohistochemistry specific
for amyloid and tau, and more recently in living individuals
using positron emission tomography (PET) scans with
ligands for amyloid [22] and/or tau [23, 24].
The most definitive and seminal studies delineating the
evolution of tau and amyloid aggregation and spreading
have been done by the research group led by Braak [25–27].
Braak et al. [27] conducted immunohistochemistry studies
of the brains of individuals who died at age 1–100, using the
antibody AT8 to recognize hyperphosphorylated tau in
abnormal tau lesions [28] and the antibody 4G8 to identify
areas of amyloid accumulation [29, 30] in the brain.
The researchers [27] have shown convincingly that AT8-
positive tau deposits, including non-argyrophilic pretangle
material, argyrophilic neuropil threads and neurofibrillary
tangles (NFT) (Fig. 3a), are present in 100 % of individuals
examined from 40 years of age on. While phosphorylation of
tau is clearly relevant for AD in the context of its aggregation
and toxicity, there is no consensus on the contribution of
phosphorylation toward the disease process leading to AD
symptoms [31]. It is not clear whether the AT8-immunore-
active pretangle material found, mostly in cases at young age
[27], is indeed a forerunner of NFTs or an irrelevant non-
specific change in tau. From the age of 40 years on, the
percentage of individuals who show spreading of AT8-pos-
itive tau to the prefrontal cortex and the neocortex (NFT
stages V and VI) is associated most significantly to AD. The
increased levels and severity of late-stage hyperphosphory-
lated tau aggregates appear to be paralleled by a similar
process of amyloid assembly, in combination ultimately
confirming the clinical diagnosis of AD (Fig. 3b).
It is intriguing that half of the 70–80 year olds in this
extensive study do not develop 4G8 positive amyloid deposits,
despite the presence of AT8-positive pretangle material or
NFTs. This observation led some researchers to suggest that a
primary tauopathy unrelated to AD exists as a benign age-
related entity that might affect all humans if they live long
enough [32] (Fig. 3b) and that the clinical diagnosis of AD can
only and exclusively be confirmed by the accelerated accu-
mulation of both p-tau and amyloid in the cortex and neo-
cortex. This could mean that p-tau accumulation may be
necessary but not sufficient to result in clinical AD or even that
AD is solely defined by amyloid plaque formation (Fig. 3c).
So far, there is no evidence to determine whether overt
clinical AD occurs in any significant number of individuals
who lack amyloid deposition in the brain and what per-
centage of the population have clinical AD at the time of
death with postmortem proof of accumulation of both
bFig. 1 a Schematic illustration of the development of Alzheimer’s
disease. A ‘healthy’ individual, somewhere in time starts to incubate
Alzheimer’s disease, indicated with an asterisk. During this incuba-
tion time or preclinical asymptomatic phase of the disease, underlying
pathology is already ongoing. In the case of AD, this might be
17 years [34]. The initiating event or situation that induces the
pathology underlying Alzheimer’s disease (the accumulation of p-tau
in the form of neurofibrillary tangles and of amyloid b plaques) is
currently not known. When the pathology has increased enough
within the incubation time of the disease, clinical symptoms appear,
and the patient will be clinically diagnosed as having Alzheimer’s
disease. Post-mortem neuropathology will confirm the clinical
diagnosis. b Diagrams illustrating the use of risk markers, time-to-
disease markers and surrogate endpoint markers in the context of
preventive interventions against HIV. In the preclinical phase of
disease, ‘healthy’ asymptomatic individuals are incubating disease.
This incubation time can be short or long. Key for the timely initiation
of a preventive intervention is the ability to mark the start (i.e.
increased risk) and length (i.e. time to disease) of this incubation time.
In the case of HIV, the marker of increased risk is a digital marker,
i.e. the presence or absence of anti-HIV antibody positivity. The viral
load is a time-to-disease predictive marker. An individual with high
HIV viral load develops AIDS in the short term (\55 months)
whereas an individual with low HIV viral load will stay AIDS free
(Adapted from de Wolf et al. [38]). c To determine efficacy of an
intervention in the preclinical phase of a disease, surrogate endpoint
markers are necessary. In the case of AIDS, the target of the
intervention (combination therapy with anti-retroviral drugs) is to
lower the viral load and thereby postpone AIDS manifestation. Viral
load is thus used as a surrogate endpoint. NFT Neurofibrillary tangles,
Ab amyloid b
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proteins in the cortex and neocortex. Duyckaerts et al. [33]
recently published a paper opposing the concept of a pri-
mary age-related tauopathy (PART) proposed by Crary
et al. arguing that ‘PART is part of AD’, as defined by low
NFT stage (I–III/IV) with no or little amyloid b deposition
(Ab phase 0–2). This debate can only be resolved by evi-
dence from extensive longitudinal cohort studies, which
unfortunately are lacking.
If AD starts in young adolescence with the first seeding
of p-tau and irreversibly leads to AD eventually, then all
humans will get AD depending on their life span, but only
if p-tau aggregation, accumulation and spreading are both
necessary and sufficient to lead to clinically manifest AD
(Fig. 3c). Currently only a minority of the world’s popu-
lation, albeit accumulating to a very significant number,



































Fig. 2 Aging: the cause, a contributor or a confounder of Alzheimer’s
disease? a Age is the dominant risk factor in Alzheimer’s disease.
Recently it was suggested by two groups that accelerated biological
aging is associated with cognitive decline [12, 16]. Based on current
available data, it cannot be distinguished whether accelerated biological
aging is a cause (upper scenario), contributor (mid scenario) or
confounder (lower scenario) of Alzheimer’s disease. Red-framed text-
boxes indicate cause(s). b Longitudinal cohort studies are necessary to
determine whether biological aging is the cause, a contributor or a
confounder of Alzheimer’s disease, and possibly to find other new
sensitive and specific predictive markers capable of describing the start
and length of the preclinical incubation period of Alzheimer’s disease
within an individual. *Start of pathological process; preclinical,
asymptomatic phase of AD; **start of clinical, symptomatic AD.
AD Alzheimer’s disease. Red arrow with series of red triangles Sam-
ples taken during longitudinal study. (Color figure online)
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Fig. 3 a Diagram illustrating the development of amyloid b (pink
box) and p-tau (blue box) pathology (adapted from Duyckaerts et al.
[33]). Post-mortem immunohistochemistry evidence of AT8-im-
munoreactive p-tau material, pretangles and NFT, appears at younger
age than 4G8-immunoreactive amyloid b deposits [27]. b Diagram il-
lustrating two hypothetical individual situations. The upper (green)
individual does not develop amyloid b or Alzheimer’s disease. Crary
et al. suggested diagnosing these cases as PART (primary age-related
tauopathy) [32]. The lower (red) individual does develop amyloid b
and AD and shows an acceleration of tauopathy after the appearance of
amyloid b [39]. P-tau stages depicted are according to the Braak stages
[27]; Amyloid b phases 1–4 are depicted according to the Thal phases
of amyloid b plaques [40]. c Diagram illustrating the two current main
hypotheses of the cause of Alzheimer’s disease. I The amyloid
hypothesis, which has been the predominant framework for research in
Alzheimer’s disease (AD), postulates that amyloid b peptide (Ab)
is the causative agent in AD. It is hypothesized that amyloid
b depositions, or possibly amyloid b oligomers, accelerate the already
ongoing benign early stages of p-tau pathology towards later stages,
eventually resulting in AD [39]. II The p-tau hypothesis postulates that
p-tau pathology is a continuum of stages of p-tau deposition, which
starts early in life with AT8-immunoreactive pretangles and eventually
causes AD. Extracellular and aggregated amyloid b depositions may
only be produced under pathological conditions by nerve cells that
contain abnormal tau (indicated with dotted blue line) [36]. Red-
framed text-boxes indicate cause. (Color figure online)
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aggregation and spreading should on its own be an ade-
quate therapy for AD if p-tau accumulation accounts for
the pathogenesis of AD.
Knowing that virtually everybody accumulates p-tau in
his or her brain, independently of any clinical signs of
AD, and taking into account the relationship between
cognitive decline and pace of biological aging, the
recently published short-term (3.8 year) longitudinal
cohort study among 70-year-olds by Villemagne et al.
[34] presents a test case for the idea that amyloid accu-
mulation is in itself sufficient and necessary to develop
AD and that there is no such thing as primary age-related
amyloidosis (PARA) (Fig. 3c). This study by researchers
in the group of Colin Masters (The Florey Institute of
Neuroscience and Mental Health, Melbourne, Australia)
argues that amyloid b deposition is ‘‘neither part of nor-
mal aging nor a benign process’’ and is a prodromal phase
of AD, reaching a ‘‘threshold of positivity at 17.0 years…
before the onset of dementia’’ [34].
Does AD start with p-tau seeding, aggregation and
spreading within the brain at young age [27], or with
amyloid b seeding, aggregation and spreading in midlife
[35], or with the accelerated combination of the two at
older age? Or are tau, amyloid and aging all confounders
and is there a yet still unknown cause of AD, such as an
environmental factor [36, 37]. Finding the answer will
depend on longitudinal natural history studies evaluating
the incubation and prodromes of AD as well as its clinical
progression of AD, in conjunction with PET scans done at
regular intervals using p-tau and amyloid ligands. Only
then can we answer the question of what induces the
seeding of either p-tau or amyloid. Only then can non-
invasive biomarker assays be qualified and validated.
How will we unravel the pathogenesis underlying AD? I
believe the way forward lies with research into specific
interventions using small molecules specifically interfering
with the overproduction of p-tau or amyloid, and/or anti-
bodies blocking the seeding, aggregation or spreading of
p-tau and/or amyloid. Observing the effects of these
interventions, given at distinct early time points in the
course of AD development, on both clinical endpoints and
quantitative PET scans might be the route to finally
resolving the question of what causes AD.
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